197 related articles for article (PubMed ID: 18079624)
1. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
[TBL] [Abstract][Full Text] [Related]
6. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Bao HY; Fang WJ; Zhang XC; Shi GM; Huang S; Yu LF; Chen J; Mou HB; Deng J; Shen P; Xu N
Cancer Chemother Pharmacol; 2011 Jan; 67(1):147-52. PubMed ID: 20221830
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A;
Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184
[TBL] [Abstract][Full Text] [Related]
11. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
13. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
[TBL] [Abstract][Full Text] [Related]
15. [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Abe H; Mafune K; Minamimura K; Abe M; Umemura A; Hirata T
Gan To Kagaku Ryoho; 2013 May; 40(5):601-4. PubMed ID: 23863581
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Kamisugi K; Matsusaka S; Imada H; Shoji D; Nakamoto E; Yokokawa T; Kawakami K; Hirata Y; Nawano K; Ogawa M; Shinozaki E; Suenaga M; Mizunuma N; Hatake K; Hama T
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1331-5. PubMed ID: 18701844
[TBL] [Abstract][Full Text] [Related]
17. [Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
Prausová J; Kubácková K; Linke Z; Kubala E; Pipková R; Hladíková J
Cas Lek Cesk; 2005; 144(11):747-51; discussion 752. PubMed ID: 16335701
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Kamnerdsupaphon P; Lorvidhaya V; Chitapanarux I; Tonusin A; Sukthomya V
J Med Assoc Thai; 2007 Oct; 90(10):2121-7. PubMed ID: 18041432
[TBL] [Abstract][Full Text] [Related]
20. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.
Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Shiozawa S; Katsube T; Naritaka Y; Ogawa K
Anticancer Res; 2007; 27(3B):1641-4. PubMed ID: 17595789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]